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In this special issue of PPAR Research, we have assembled a
comprehensive and complementary group of review articles
and original investigations that illustrate the pivotal role of
the PPAR family of nuclear hormone receptors in the regu-
lation of fundamental cellular events in the lung. The lung
performs the vital function of gas exchange required for the
deliveryof oxygento tissues.In performingthisfunction, the
lung is continuously exposed to a diverse array of microbial
pathogens, allergens, and toxic particulate matter. These in-
sults require immune and reparative responses that are ap-
propriate, yet tightly regulated in order to maintain the del-
icate alveolar structures required for eﬃcient gas exchange.
PPARs and their obligatory heterodimer partners retinoid X
receptors (RXR) are well known to regulate the expression
of genes involved in lipid and glucose metabolism. More re-
cently, these transcription factors have been shown to modu-
late developmental, inﬂammatory, and reparative responses,
including those that occur in the lung.
Articles included in this special issue highlight the im-
portance of PPARs and RXR in lung biology and in the
pathogenesis of lung disease. Both PPAR-γ and RXR partici-
pate in lung morphogenesis, including the processes of post-
natal alveolar elastogenesis and maturation.The majority of
studies reported to date support a role for PPAR-α and/or
PPAR-γ in inhibiting the release of inﬂammatory mediators
from lung immune and stromal/parenchymal cells in vitro,
and dampening inﬂammation and damage in animal mod-
els of acute lung injury (ALI), ischemia-reperfusion injury,
and allergic airways inﬂammation. Emerging evidence indi-
cates that PPAR family members can also suppress prolif-
erative and diﬀerentiation responses of lung epithelial cells,
smooth muscle cells, and ﬁbroblasts, which is of particular
relevancetotissueremodelingandﬁbroproliferationthatoc-
cur in chronic airways disease, ALI, pulmonary vascular dis-
ease, and pulmonary ﬁbrosis. In contrast to these notable
inhibitory eﬀects, PPAR-γ can also activate key macrophage
antimicrobial and reparative responses, in part by enhancing
the expression of cell surface receptors required for ingestion
of microbes and cellular debris present within the airspace.
Finally, data is summarized to illuminate the central role of
PPAR-γ inregulatingcriticalaspectsoflungtumorinitiation,
progression, and metastasis. Speciﬁc eﬀects include promo-
tion of tumor cell diﬀerentiation, induction of cell cycle ar-
rest and apoptosis, suppression of angiogenesis, and modu-
lation of immune/stromal cells within the tumor microenvi-
ronment.
The ﬁeld of PPAR research continues to be hindered by
the nonselective eﬀects of synthetic and naturally occurring
agonists, the limited availability of potent and speciﬁc in-
hibitors, and the absence of ideal genetic models of PPAR
deﬁciency. The introduction of new molecular tools and the
generation of conditionally targeted and site speciﬁc (in-
cluding lung epithelial cell-speciﬁc) PPAR-γ deﬁcient mice
will allow better distinction between PPAR-dependent and
PPAR-independent eﬀects. Moreover, the search for relevant
endogenous PPAR ligands continues. The recently described
nitroalkene species are appealing candidates, although the
presence of these molecules in lung tissues has not yet been
characterized.
We thank the editors for the opportunity to share with
the readership this important area of investigation. It is our
hope that this special issue will serve as a catalyst for new
initiatives in this exciting and rapidly evolving ﬁeld. Obser-
vations made at the bench have already transitioned to the2 PPAR Research
bedside, as trials assessing eﬀects of PPAR-γ agonists in the
treatmentofdiverselungdiseases,includingasthmaandlung
cancer, are ongoing.
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